Paracrine mechanisms of endothelial progenitor cells in vascular repair

Yan, Fanchen; Liu, Xiaodan; Ding, Huang; Zhang, Wei

doi:10.1016/j.acthis.2021.151833

Cited by 28 publications

(18 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This co-creative property inherently applies to EPCs in regenerative tissues. EPCs secrete multiple factors for both anti-inflammation and immunosuppression, such as VEGF ( Jarajapu et al, 2014 ), PGE2 ( Carneiro et al, 2019 ), TGF-β ( Acosta et al, 2019 ), IL-4, IL-6 ( Kado et al, 2018 ), IL-10 ( Zullo et al, 2015 ) and G-CSF ( Wen et al, 2019 ; Alwjwaj et al, 2021 ; Yan et al, 2022 ). Especially, IL-10 and TGF-β are expressed and play a key role in immunomodulation and anti-inflammation in CD34 + cells from PB or BM ( Majka et al, 2001 ; Ratajczak et al, 2013 ; Jarajapu et al, 2014 ).…”

Section: Cd34 + Cells As Commanders For Angiogenes...mentioning

confidence: 99%

CD34 positive cells as endothelial progenitor cells in biology and medicine

Hassanpour

Salybekov

Kobayashi

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34+ cells has attracted interest for application in patients with various vascular, ischemic, and inflammatory diseases. CD34+ cells have recently been reported to improve therapeutic angiogenesis in a variety of diseases. Mechanistically, CD34+ cells are involved in both direct incorporation into the expanding vasculature and paracrine activity through angiogenesis, anti-inflammatory, immunomodulatory, and anti-apoptosis/fibrosis roles, which support the developing microvasculature. Preclinical, pilot, and clinical trials have well documented a track record of safety, practicality, and validity of CD34+ cell therapy in various diseases. However, the clinical application of CD34+ cell therapy has triggered scientific debates and controversies in last decade. This review covers all preexisting scientific literature and prepares an overview of the comprehensive biology of CD34+ cells as well as the preclinical/clinical details of CD34+ cell therapy for regenerative medicine.

show abstract

Section: Cd34 + Cells As Commanders For Angiogenes...mentioning

confidence: 99%

CD34 positive cells as endothelial progenitor cells in biology and medicine

Hassanpour

Salybekov

Kobayashi

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…EPCs secrete various cytokines, growth factors, lipids and ECM, providing nutritional and anti-apoptotic support for circulating resident EPCs and other cells such as ECs, cardiomyocytes, MSCs and neural stem cells. EPCs’ paracrine production can be categorized into three types: (1) secretion of cytokines such as VEGF, SDF-1, PDGF, G-CSF, growth factors and chemokines to promote angiogenesis and EC proliferation and migration; (2) participation in intercellular communication by secreting extracellular vesicles such as apoptotic bodies, microvesicles and exosomes; and (3) connecting to ECs via nanotubes which allow the transfer of molecules such as proteins, RNA and other substances between cells [ 104 ].…”

Section: Vascular Progenitor Cells In Cancersmentioning

confidence: 99%

Vascular Progenitor Cells: From Cancer to Tissue Repair

Barachini

Ghelardoni

Madonna

2023

JCM

View full text Add to dashboard Cite

Vascular progenitor cells are activated to repair and form a neointima following vascular damage such as hypertension, atherosclerosis, diabetes, trauma, hypoxia, primary cancerous lesions and metastases as well as catheter interventions. They play a key role not only in the resolution of the vascular lesion but also in the adult neovascularization and angiogenesis sprouting (i.e., the growth of new capillaries from pre-existing ones), often associated with carcinogenesis, favoring the formation of metastases, survival and progression of tumors. In this review, we discuss the biology, cellular plasticity and pathophysiology of different vascular progenitor cells, including their origins (sources), stimuli and activated pathways that induce differentiation, isolation and characterization. We focus on their role in tumor-induced vascular injury and discuss their implications in promoting tumor angiogenesis during cancer proliferation and migration.

show abstract

“…This was because when blood vessels were stimulated by ischemia and hypoxia, BM-derived EPCs were targeted from the BM to the periphery and chemotactically migrated to the ischemic injury site. There, they differentiated into mature vascular endothelial cells, forming neovascularization during angiogenesis, or indirectly playing the role in angiogenesis in a paracrine manner by secreting cytokines that promote angiogenesis, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and angiotensin [16]. Current studies have shown that extracellular vesicles secreted by EPCs can act independently as a bioactive substance to transmit information in cells and participate in the process of angiogenesis [6].…”

Section: Overview Of Epcsmentioning

confidence: 99%

Advances in the Pharmacological Intervention of Endothelial Progenitor Cells in the Treatment of Ischemic Stroke

Zhu

Zhang

et al. 2022

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: Ischemic stroke, a common central nervous system disease that seriously threatens human life and health, is characterized by rapid progress and a high disability fatality rate. Ischemic tissue can produce a large amount of vascular endothelial growth factor (VEGF) and stromal cell-derived factor 1 (SDF-1) to promote the mobilization of endothelial progenitor cells (EPCs). Summary: As newly discovered stem cells, EPCs can promote angiogenesis in ischemic tissue, repair the damaged vascular endothelium, and maintain vascular homeostasis. Thus, EPCs have become a new research hotspot in this field. This review focuses on the mechanism of EPCs and the intervention of various novel drugs, including small molecules and biomolecules, which will promote the capture, proliferation, and differentiation of EPCs. Then, we explore the promotion of vascular health and the prospect of its application in the treatment of cerebral ischemic stroke (CIS). Key Message: It is clinically significant to study the potential of new drug therapy to target EPCs. More effective cytokines, signal pathways, and other drugs should be explored in the future and their specific mechanisms determined. Research should reveal more biological functions of EPCs and achieve their efficient amplification to improve therapy against CIS stroke.

show abstract

Paracrine mechanisms of endothelial progenitor cells in vascular repair

Cited by 28 publications

References 106 publications

CD34 positive cells as endothelial progenitor cells in biology and medicine

CD34 positive cells as endothelial progenitor cells in biology and medicine

Vascular Progenitor Cells: From Cancer to Tissue Repair

Advances in the Pharmacological Intervention of Endothelial Progenitor Cells in the Treatment of Ischemic Stroke

Contact Info

Product

Resources

About